Garry Nolan

Administrative Appointments

• Director, Stanford NHLBI Proteomics Center, National Heart, Lung, and Blood Institute of the NIH (2002 - 2009)

Honors and Awards

• Stohlman Scholar, Leukemia and Lymphoma Society (2000)
• Scholar of the Leukemia Society, Leukemia and Lymphoma Society (1996-2000)
• Burrough's Wellcome Investigator's Award In Pharmacology, Burroughs Wellcome (1995-2000)

Professional Education

Postdoctoral Advisees

Sean Bendall, Bernd Bodenmiller, Kara Davis, Matthew Hale, Faye Hsu, Shigeru Okumura, Jason Ptacek, Karen Sachs, Eli Zunder

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Immunology
• Microbiology and Immunology

Web Site Links

• Nolan Lab

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Control of T cell signaling, machine learning of signaling states by systems biology, and leukemia/cancer autoimmunity are prominent in our studies. We use advanced Flow Cytometric analysis (FACS) of phosphoproteins in single cells to achieve many of our goals. Signaling systems can now be analyzed directly by flow cytometry and Fluorescence Activated Cell Sorting, primarily through technologies developed in our laboratory, focused on following multiple phosphoproteins in complex populations of primary cells such as mouse cells and even clinical samples. Up to 15 simultaneous parameters can be followed in single cells including multiple kinases, phosphoproteins, cell cycle proteins, and other parameters, enabling resolution of cellular activation states.

We are using these techniques to study B and T cell signaling, dendritic cell function, and other immune parameters by analysis of biochemical functions at the single cell level. Recently, we have begun using the approach to distinguish predictive patterns of intracellular signaling to classify patient responses to chemotherapies and to determine how their signaling systems are altered in disease states. We are also using the technique for drug screening in primary cells to truly select for drugs with efficacies in certain cell subsets but not others.

Autoimmune diseases in which we have particular interest include rheumatoid arthritis and systemic lupus erythematosus. In these diseases, we focus on understanding how the immune system becomes dysregulated as disease comes and goes. We can measure and determine the cellular network states in multiple cell subsets. In cancer, we are working in follicular lymphoma as well as acute myelogenous leukemia where we can look at disease progression as a measure of changes in disease states correlated to particular genetic changes in the genome of human cancer cells. Also we have made determined efforts in understanding how the micro-environment of...

Clinical Trials

• Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Recruiting

Publications

• Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. Cancer Cell. 2008; 14 (4): 335-43
• What's wrong with drug screening today. Nolan GP, Nat Chem Biol. 2007; 3 (4): 187-91
• Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. Danna EA, Nolan GP. Curr Opin Chem Biol. 2006; 10 (1): 20-7
• Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Irish JM, Kotecha N, Nolan GP. Nat Rev Cancer. 2006; 6 (2): 146-55
• Causal protein-signaling networks derived from multiparameter single-cell data. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Science. 2005; 308 (5721): 523-9